How do clinicians integrate oral octreotide into their treatment plan for acromegaly?

Affiliations

Comment

Maya B Lodish. Lancet Diabetes Endocrinol. 2022 Feb.

. 2022 Feb;10(2):86-87.

doi: 10.1016/S2213-8587(21)00319-3. Epub 2021 Dec 22.

¹ Department of Pediatric Endocrinology, University of California, San Francisco, CA 94143, USA. Electronic address: maya.lodish@ucsf.edu.

No abstract available

Conflict of interest statement

I declare no competing interests.

Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial.
Fleseriu M, Dreval A, Bondar I, Vagapova G, Macut D, Pokramovich YG, Molitch ME, Leonova N, Raverot G, Grineva E, Poteshkin YE, Gilgun-Sherki Y, Ludlam WH, Patou G, Haviv A, Gordon MB, Biermasz NR, Melmed S, Strasburger CJ. Fleseriu M, et al. Lancet Diabetes Endocrinol. 2022 Feb;10(2):102-111. doi: 10.1016/S2213-8587(21)00296-5. Epub 2021 Dec 22. Lancet Diabetes Endocrinol. 2022. PMID: 34953531 Clinical Trial.